Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
346 hedge funds and large institutions have $6.15B invested in Intra-Cellular Therapies Inc. in 2024 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 121 increasing their positions, 127 reducing their positions, and 39 closing their positions.
226% more call options, than puts
Call options by funds: $314M | Put options by funds: $96.1M
44% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 39
4% more funds holding
Funds holding: 333 → 346 (+13)
5% less repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 127
5% less capital invested
Capital invested by funds: $6.5B → $6.15B (-$357M)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$65.1M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$46.7M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$23.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$22.4M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$106M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$66.5M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$35.3M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$34.4M |
| 5 |
Holocene Advisors
New York
|
-$24.2M |
ITCI Hedge Fund Activity: Q1 2024 in Review
346 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2024, worth a combined $6.15B — down 5.5% from $6.5B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new ITCI positions and 39 closed out — a net gain of 17 holders — while 121 added to existing stakes and 127 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $65.1M. The largest seller was Morgan Stanley, cutting an estimated $106M.
- 346 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2024, up from 333 in Q4 2023.
- Funds reported $6.15B of Intra-Cellular Therapies Inc. stock for Q1 2024, down 5.5% quarter-over-quarter.
- 56 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2024 and 39 closed out, a net change of +17 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q1 2024 was Perceptive Advisors, an estimated $65.1M added.
- The largest Intra-Cellular Therapies Inc. seller in Q1 2024 was Morgan Stanley, an estimated $106M sold.
Based on aggregated 13F filings for Q1 2024.